{"doi":"10.2147/ndt.s221242","title":"&lt;p&gt;Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies&lt;/p&gt;","abstract":null,"journal":"Neuropsychiatric Disease and Treatment","year":2020,"id":659898,"datarank":0.47032413238937254,"base_score":3.1354942159291497,"endowment":3.1354942159291497,"self_citation_contribution":0.47032413238937254,"citation_network_contribution":0.0,"self_endowment_contribution":0.47032413238937254,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":22,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":605561,"name":"Srihari Gopal","orcid":"0000-0001-5254-2192","position":1,"is_corresponding":false},{"id":251255,"name":"Arun Singh","orcid":"0000-0003-4273-542X","position":2,"is_corresponding":false},{"id":1722581,"name":"Isaac Nuamah","orcid":null,"position":3,"is_corresponding":false},{"id":1722582,"name":"Katalin Pungor","orcid":"0000-0003-4679-2050","position":4,"is_corresponding":false},{"id":1722583,"name":"Wilson Tan","orcid":"0000-0003-4832-156X","position":5,"is_corresponding":false},{"id":1722584,"name":"Bernardo Soares","orcid":null,"position":6,"is_corresponding":false},{"id":278033,"name":"Edward Kim","orcid":"0000-0002-7715-4054","position":7,"is_corresponding":false},{"id":1722585,"name":"Adam J Savitz","orcid":null,"position":8,"is_corresponding":false},{"id":1722580,"name":"Maju Mathews","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"&lt;p&gt;Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies&lt;/p&gt;","abstract":"BACKGROUND: Sudden discontinuation from antipsychotic treatment is a common occurrence in patients with schizophrenia. Lower rates of relapse could be expected for patients discontinuing treatment from longer-acting formulations vs their shorter-acting equivalents. OBJECTIVE: To compare relapse rates and time-to-relapse between the active (analogous to adherent patients) and placebo (analogous to non-adherent patients in the real-world) arms of three different formulations of paliperidone (oral paliperidone extended release [paliperidone ER], paliperidone palmitate once monthly [PP1M], and paliperidone palmitate three monthly [PP3M] long-acting injectables). METHODS: Data from three similarly designed, randomized relapse prevention studies in adult patients with schizophrenia were analyzed. RESULTS: In total, 922 patients were included (active treatment: 473, placebo: 449). Lowest percentage of patients experienced relapse with PP3M <PP1M <paliperidone and ER, in both the active treatment (PP3M, 9% <PP1M, 18% <paliperidone ER, 22%) and placebo (PP3M, 29% <PP1M, 48% <paliperidone ER, 52%) groups. The post-discontinuation median-time-to-relapse was significantly longer with PP3M (395 days [274 days to \"not-reached\"])> PP1M (172 days [134-222 days])> paliperidone ER (58 days [42-114 days]) and was \"not-estimable\" in the active treatment group due to low relapse rates. Hazard ratios (HR) of the three paliperidone formulations relative to their respective placebos were PP3M ([HR: 3.81; 95% CI: 2.08, 6.99; P< 0.0001]> PP1M [HR: 3.60; 95% CI: 2.45, 5.28; P<0.0001]> paliperidone ER [HR: 2.83; 95% CI: 1.73, 4.63; P<0.001]). CONCLUSION: paliperidone ER (NCT00086320), PP1M (NCT00111189), and PP3M (NCT01529515).","is_dataset_classified":null,"base_score":3.1354942159291497,"endowment":3.1354942159291497,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"32606705","pmcid":"PMC7311166","openalex_id":"https://openalex.org/W3036040035","authors":[],"funders":[],"total_grants":0,"fwci":1.8398,"citation_percentile":0.85462921,"influential_citations":0,"citation_trend":[{"year":2021,"count":3},{"year":2022,"count":4},{"year":2023,"count":6},{"year":2024,"count":3},{"year":2025,"count":2},{"year":2026,"count":4}],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"https://www.dovepress.com/getfile.php?fileID=58992","host_type":"journal"},{"url":"https://www.dovepress.com/getfile.php?fileID=58992","host_type":"publisher"},{"url":"https://doi.org/10.2147/ndt.s221242","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/32606705","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7311166","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC7311166","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC7311166?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Schizophrenia research and treatment","Healthcare Decision-Making and Restraints","Pharmacovigilance and Adverse Drug Reactions"],"mesh_terms":[],"keywords":["Paliperidone","Paliperidone Palmitate","Medicine","Discontinuation","Antipsychotic","Post-hoc analysis","Placebo","Hazard ratio","Internal medicine","Schizophrenia (object-oriented programming)","Pharmacology","Confidence interval","Psychiatry","Schizophrenia","Relapse Prevention","Paliperidone Palmitate Once Monthly","Oral Paliperidone Extended Release","Paliperidone Palmitate Three Monthly"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-12T07:53:19.838691Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}